Revvity Signals Banner Ad (Nov-Dec)

EDITORIAL SECTION

KNOWLEDGE BANK

  • Techno Trends

    Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment

    Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment

TOP ARTICLES

press releasesRead more...

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

Regeneron Pharmaceuticals Inc NASDAQ REGN today announced that the US Food and Drug Administration FDA has approved Livsayis cemdisiran for the treatment of generalized myasthenia gravis gMG in adult patients

22nd Edition Project Portfolio and Resource Management Excellence for Pharma and BioTech

Pharma organisations are still in a transition process from traditional model centered on blockbuster to more collaborative global ones In order to address the main challenge of RD productivity PPM professional serve as a link between operational teams and senior management level They have the role...

Shionogi Completes Acquisition of IntraBio Inc. and Adds AQNEURSA® (levacetylleucine) to Growing Rare Disease Global Portfolio

Shionogi Co Ltd Head Office Osaka Japan Chief Executive Officer Isao Teshirogi PhD hereafter Shionogi announced that it has completed the acquisition of IntraBio Inc IntraBio The acquisition adds AQNEURSA levacetylleucine and additional rare disease capabilities to Shionogis growing global portfoli...

Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer

GSK plc LSENYSE GSK today announced the US Food and Drug Administration FDA has granted accelerated approval to Nelkarmi neladalkib for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

03 - 04

Dec 2026

LATEST NEWSRead more...

Scientist.com Launches AI-Ready Market Intelligence Platform for Biopharma R&D

Scientistcom has launched Pharma Observatory a market intelligence platform designed to help biopharmaceutical research and development RD teams understand the competitive landscape surrounding their programmes The platform provides insights into competing research programmes potential business part...

Erasca Partners with Bristol Myers Squibb to Evaluate ERAS-0015 Combination Therapy for Pancreatic Cancer

Clinicalstage precision oncology company Erasca has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMS to evaluate its investigational drug ERAS in combination with navlimetostat BMS an investigational PRMT inhibitor developed by BMS

GATC Health and Hesperos Join Forces to Develop AI and Human-on-a-Chip Workflow for Preclinical Testing

GATC Health Corp and Hesperos Inc have entered into a strategic collaboration to develop an integrated New Approach Methodologies NAMs workflow aimed at reducing the time and cost of preclinical drug testing before human clinical trials

Novartis’ Cosentyx becomes first anti-IL-17 biologic approved for polymyalgia rheumatica

Novartis has received approval from the US Food and Drug Administration FDA for Cosentyx secukinumab mg to treat adults with polymyalgia rheumatica PMR who have not responded adequately to corticosteroids or cannot tolerate a reduction in their corticosteroid dose

Roche’s Gazyva/Gazyvaro becomes first FDA-approved treatment for primary membranous nephropathy

Roche has received approval from the US Food and Drug Administration FDA for GazyvaGazyvaro obinutuzumab to treat adults with primary membranous nephropathy pMN who are at risk of disease progression

Cyclarity Therapeutics Receives FDA Clearance for UDP-003 Clinical Trial Application in the US

Cyclarity Therapeutics Inc has received clearance from the US Food and Drug Administration FDA for its Investigational New Drug IND application for UDP enabling the company to expand its atherosclerosis clinical development programme into the United States